CSPC Innovation Pharmaceutical Co., Ltd. (SHE:300765)
China · Delayed Price · Currency is CNY 30.16
-1.49 (-4.71%)
Mar 20, 2026, 3:04 PM CST
SHE:300765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,114 | 1,928 | 2,485 | 2,571 | 1,790 |
Other Revenue | 43.33 | 52.64 | 53.66 | 55.25 | 60.14 |
| 2,158 | 1,981 | 2,539 | 2,626 | 1,850 | |
Revenue Growth (YoY) | 8.93% | -21.98% | -3.34% | 42.00% | 40.40% |
Cost of Revenue | 1,338 | 1,155 | 1,383 | 1,493 | 1,043 |
Gross Profit | 819.96 | 825.52 | 1,155 | 1,133 | 807.09 |
Selling, General & Admin | 372.76 | 233.37 | 302.21 | 312.29 | 323.91 |
Research & Development | 1,036 | 842.2 | 671.4 | 46.3 | 26.5 |
Other Operating Expenses | 28.93 | 29.57 | 32.73 | 19.92 | 15.75 |
Operating Expenses | 1,446 | 1,102 | 1,001 | 386.31 | 372.19 |
Operating Income | -625.75 | -276.66 | 153.8 | 747.14 | 434.9 |
Interest Expense | -21.82 | -6.37 | -17.63 | -0.22 | -2.83 |
Interest & Investment Income | 11.06 | 42.21 | 85.92 | 49.57 | 45.37 |
Currency Exchange Gain (Loss) | 18.56 | 7.44 | 25.17 | 55.21 | -7.07 |
Other Non Operating Income (Expenses) | -0.6 | -1.07 | 1.4 | -0.98 | -1.08 |
EBT Excluding Unusual Items | -618.55 | -234.45 | 248.65 | 850.72 | 469.29 |
Impairment of Goodwill | - | - | - | - | -3.47 |
Gain (Loss) on Sale of Investments | -7.03 | -0.89 | - | - | 3.59 |
Gain (Loss) on Sale of Assets | 2.78 | 0.71 | 0.33 | 1.61 | 0.38 |
Asset Writedown | -3.66 | -3.1 | -2.15 | -6.17 | -10.1 |
Other Unusual Items | 74.91 | 16.43 | 15.15 | 5.22 | 18.3 |
Pretax Income | -551.54 | -221.3 | 262.14 | 851.37 | 477.99 |
Income Tax Expense | 57.8 | 81.91 | 136.47 | 124.76 | 85.29 |
Earnings From Continuing Operations | -609.34 | -303.21 | 125.67 | 726.61 | 392.7 |
Minority Interest in Earnings | 368.21 | 356.94 | 308.77 | -0.33 | 0.53 |
Net Income | -241.13 | 53.73 | 434.44 | 726.28 | 393.23 |
Net Income to Common | -241.13 | 53.73 | 434.44 | 726.28 | 393.23 |
Net Income Growth | - | -87.63% | -40.18% | 84.70% | 31.15% |
Shares Outstanding (Basic) | 1,393 | 1,399 | 1,397 | 1,337 | 1,337 |
Shares Outstanding (Diluted) | 1,393 | 1,399 | 1,397 | 1,337 | 1,337 |
Shares Change (YoY) | -0.44% | 0.16% | 4.50% | -0.02% | 13.53% |
EPS (Basic) | -0.17 | 0.04 | 0.31 | 0.54 | 0.29 |
EPS (Diluted) | -0.17 | 0.04 | 0.31 | 0.54 | 0.29 |
EPS Growth | - | -87.65% | -42.76% | 84.73% | 15.52% |
Free Cash Flow | -764.08 | -1,713 | 139.72 | 526.67 | 96.67 |
Free Cash Flow Per Share | -0.55 | -1.22 | 0.10 | 0.39 | 0.07 |
Dividend Per Share | - | 0.020 | 0.267 | 0.069 | 0.069 |
Dividend Growth | - | -92.50% | 284.29% | - | 94.94% |
Gross Margin | 38.00% | 41.68% | 45.51% | 43.15% | 43.63% |
Operating Margin | -29.00% | -13.97% | 6.06% | 28.45% | 23.51% |
Profit Margin | -11.18% | 2.71% | 17.11% | 27.65% | 21.26% |
Free Cash Flow Margin | -35.41% | -86.47% | 5.50% | 20.05% | 5.23% |
EBITDA | -403.57 | -60.31 | 308.55 | 819.26 | 504.05 |
EBITDA Margin | -18.70% | -3.04% | 12.15% | 31.19% | 27.25% |
D&A For EBITDA | 222.17 | 216.35 | 154.76 | 72.12 | 69.15 |
EBIT | -625.75 | -276.66 | 153.8 | 747.14 | 434.9 |
EBIT Margin | -29.00% | -13.97% | 6.06% | 28.45% | 23.51% |
Effective Tax Rate | - | - | 52.06% | 14.65% | 17.84% |
Revenue as Reported | 2,158 | 1,981 | 2,539 | 2,626 | 1,850 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.